Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model

S N Shchelkunov; I A Razumov; I V Kolosova; A V Romashchenko; E L Zavjalov

doi:10.1134/S1607672918010088

Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model

Dokl Biochem Biophys. 2018 Jan;478(1):30-33. doi: 10.1134/S1607672918010088. Epub 2018 Mar 14.

Authors

S N Shchelkunov^{1

2

3}, I A Razumov⁴, I V Kolosova⁵, A V Romashchenko⁴, E L Zavjalov⁴

Affiliations

¹ Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia. [email protected].
² Vector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia. [email protected].
³ Novosibirsk State University, Novosibirsk, 630090, Russia. [email protected].
⁴ Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.
⁵ Vector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia.

PMID: 29536305
DOI: 10.1134/S1607672918010088

Abstract

The possibility of glioblastoma virotherapy at intravenous injection of the LIVP-GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP-GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP-GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.

MeSH terms

Animals
Cell Line, Tumor
Cell Transformation, Neoplastic*
Disease Models, Animal
Glioblastoma / pathology*
Glioblastoma / therapy*
Glioblastoma / virology
Humans
Mice
Mice, SCID
Oncolytic Virotherapy*
Tumor Burden